North America Ophthalmic Drugs Market Forecast 2023-2032

The North America ophthalmic drugs market is projected to record a CAGR of 5.56% during the forecast period, 2023-2032. Growing awareness of eye health and the accessibility of eye care services are fostering early detection and treatment of eye conditions. This pattern is fueling the expansion of the ophthalmic drugs market in North America.

MARKET INSIGHTS

Canada and the United States are evaluated for the North America ophthalmic drugs market growth assessment. The surge in eye diseases, particularly those associated with aging and lifestyle, is fueling the need for ophthalmic drugs. Progress in drug delivery technologies is amplifying drug effectiveness and patient adherence, contributing to market expansion. With an increasing elderly population in the United States, there is a heightened vulnerability to age-related eye conditions, driving up the demand for ophthalmic drugs. The pharmaceutical industry's dedication to research and development is yielding the creation of advanced ophthalmic drugs, marking a significant stride forward.

The ophthalmic drugs market in the United States is dominated by key players such as Novartis AG, Allergan (now a part of AbbVie Inc), Regeneron Pharmaceuticals, Santen Pharmaceutical Co Ltd, and Bausch Health Companies Inc. These industry leaders consistently invest in research and development, aiming to introduce novel and advanced ophthalmic drugs to the market. This ongoing commitment plays a pivotal role in fostering the growth and progression of eye care in the United States.

COMPETITIVE INSIGHTS

Some of the leading players in the North America ophthalmic drugs market include: Bausch Health Companies Inc, Pfizer Inc, AbbVie Inc, etc.

Our report offerings include:

Explore key findings of the overall market
Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
Market Segmentation caters to a thorough assessment of key segments with their market estimations
Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 73999

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON OPHTHALMIC DRUGS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. EMERGING THERAPIES FOR DRY EYE SYNDROME
- 2.5.2. GROWING DEMAND FOR COMBINATION THERAPIES
- 2.5.3. INCREASING INVESTMENT IN RESEARCH & DEVELOPMENT
- 2.5.4. SHIFT TOWARD OVER-THE-COUNTER (OTC) PRODUCTS

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. AGING POPULATION'S SUSCEPTIBILITY TO AGE-RELATED EYE CONDITIONS
- 3.1.2. ADVANCEMENTS IN DRUG DELIVERY TECHNOLOGIES
- 3.1.3. RISING PREVALENCE OF EYE DISEASES AND DISORDERS
- 3.1.4. FAVORABLE REIMBURSEMENT POLICIES BY HEALTHCARE SYSTEMS
3.2. KEY RESTRAINTS
- 3.2.1. DELAY IN DRUG APPROVALS
- 3.2.2. SIDE EFFECTS RELATED TO OPHTHALMIC DRUGS

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
4.2. TECHNOLOGY SNAPSHOT
- 4.2.1. BIOLOGICS
- 4.2.2. CELL THERAPY
- 4.2.3. GENE THERAPY
- 4.2.4. DRUG DELIVERY
- 4.2.5. SMALL MOLECULE
- 4.2.6. OTHER TECHNOLOGIES
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. KEY BUYING CRITERIA
4.8. REGULATORY FRAMEWORK

5. MARKET BY INDICATION

5.1. DRY EYE
5.2. GLAUCOMA
5.3. INFECTION/INFLAMMATION/ALLERGIES
5.4. RETINAL DISORDER
- 5.4.1. WET AGE-RELATED MACULAR DEGENERATION
- 5.4.2. DRY AGE-RELATED MACULAR DEGENERATION
- 5.4.3. DIABETIC RETINOPATHY
- 5.4.4. OTHER RETINAL DISORDERS
5.5. OTHER INDICATIONS

6. MARKET BY TYPE

6.1. PRESCRIPTION DRUGS
6.2. OVER-THE-COUNTER DRUGS

7. MARKET BY DOSAGE FORM

7.1. GELS
7.2. EYE SOLUTIONS & SUSPENSIONS
7.3. CAPSULES & TABLETS
7.4. EYE DROPS
7.5. OINTMENTS

8. MARKET BY THERAPEUTIC CLASS

8.1. ANTI-GLAUCOMA
8.2. ANTI-INFECTION
8.3. ANTI-INFLAMMATORY
8.4. ANTI-ALLERGY
8.5. OTHER THERAPEUTIC CLASSES

9. MARKET BY DISTRIBUTION CHANNEL

9.1. HOSPITAL PHARMACIES
9.2. DRUG STORES
9.3. ONLINE PHARMACIES
9.4. OTHER DISTRIBUTION CHANNELS

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. NORTH AMERICA OPHTHALMIC DRUGS MARKET DRIVERS
- 10.1.3. NORTH AMERICA OPHTHALMIC DRUGS MARKET CHALLENGES
- 10.1.4. KEY PLAYERS IN NORTH AMERICA OPHTHALMIC DRUGS MARKET
- 10.1.5. COUNTRY ANALYSIS
  - 10.1.5.1. UNITED STATES
  - 10.1.5.1.1. UNITED STATES OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES
  - 10.1.5.2. CANADA
  - 10.1.5.2.1. CANADA OPHTHALMIC DRUGS MARKET SIZE & OPPORTUNITIES

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
11.2. COMPANY PROFILES
- 11.2.1. ABBVIE INC
  - 11.2.1.1. COMPANY OVERVIEW
  - 11.2.1.2. PRODUCTS & SERVICES
  - 11.2.1.3. STRENGTHS & CHALLENGES
- 11.2.2. ACCUTOME INC
  - 11.2.2.1. COMPANY OVERVIEW
  - 11.2.2.2. PRODUCTS & SERVICES
  - 11.2.2.3. STRENGTHS & CHALLENGES
- 11.2.3. BAUSCH HEALTH COMPANIES INC
  - 11.2.3.1. COMPANY OVERVIEW
  - 11.2.3.2. PRODUCTS & SERVICES
  - 11.2.3.3. STRENGTHS & CHALLENGES
- 11.2.4. GENENTECH INC
  - 11.2.4.1. COMPANY OVERVIEW
  - 11.2.4.2. PRODUCTS & SERVICES
  - 11.2.4.3. STRENGTHS & CHALLENGES
- 11.2.5. JOHNSON & JOHNSON
  - 11.2.5.1. COMPANY OVERVIEW
  - 11.2.5.2. PRODUCTS & SERVICES
  - 11.2.5.3. STRENGTHS & CHALLENGES
- 11.2.6. THEA PHARMA INC
  - 11.2.6.1. COMPANY OVERVIEW
  - 11.2.6.2. PRODUCTS & SERVICES
  - 11.2.6.3. STRENGTHS & CHALLENGES
- 11.2.7. NOVARTIS AG
  - 11.2.7.1. COMPANY OVERVIEW
  - 11.2.7.2. PRODUCTS & SERVICES
  - 11.2.7.3. STRENGTHS & CHALLENGES
- 11.2.8. PFIZER INC
  - 11.2.8.1. COMPANY OVERVIEW
  - 11.2.8.2. PRODUCTS & SERVICES
  - 11.2.8.3. STRENGTHS & CHALLENGES
- 11.2.9. REGENERON PHARMACEUTICALS INC
  - 11.2.9.1. COMPANY OVERVIEW
  - 11.2.9.2. PRODUCTS & SERVICES
  - 11.2.9.3. STRENGTHS & CHALLENGES
- 11.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 11.2.10.1. COMPANY OVERVIEW
  - 11.2.10.2. PRODUCTS & SERVICES
  - 11.2.10.3. STRENGTHS & CHALLENGES
- 11.2.11. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 11.2.11.1. COMPANY OVERVIEW
  - 11.2.11.2. PRODUCTS & SERVICES
  - 11.2.11.3. STRENGTHS & CHALLENGES
- 11.2.12. TEVA PHARMACEUTICALS INDUSTRIES LTD
  - 11.2.12.1. COMPANY OVERVIEW
  - 11.2.12.2. PRODUCTS & SERVICES
  - 11.2.12.3. STRENGTHS & CHALLENGES